At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 37 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
In Brief
A Phase 3 clinical trial evaluating Ixazomib for Multiple Myeloma. Completed, enrolled 37 participants across 10 sites.
Detailed Summary
The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartJan 2019
Primary CompletionDec 2023
TodayJul 2026
First PostedNov 21, 2018
Enrollment StartJan 24, 2019
Primary CompletionDec 6, 2023
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.6 years ago
Interventions
Ixazomibdrug
Ixazomib Capsules